Multi-modal Assessment of GABA Function in Psychosis (GABAmech)

  • STATUS
    Recruiting
  • End date
    Feb 28, 2025
  • participants needed
    232
  • sponsor
    University of Michigan
Updated on 12 October 2022
remission
anxiety
benzodiazepines
psychosis
bipolar disorder
depressive disorder
psychiatric disorder
antipsychotics
psychotropic drugs
suicide
suicidal
schizophrenia
lorazepam
major depressive disorder
functional magnetic resonance imaging
schizoaffective disorder
psychotic symptoms
schizophreniform disorder
substance use disorder
gamma-aminobutyric acid
gamma-aminobutyric acid (gaba)
Accepts healthy volunteers

Summary

The purpose of this study is to better understand mental illness and will test the hypotheses that while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after lorazepam.

This study will enroll participants between the ages of 16 and 60, who have a psychotic illness (such as psychosis which includes conditions like schizophrenia, schizoaffective disorder, and mood disorders). The study will also enroll eligible participants without any psychiatric illness, to compare their brains.

The study will require participants to have 3-4 sessions over a few weeks. The initial assessments (may be over two visits) will include a diagnostic interview and several questionnaires (qols) to assess eligibility. Subsequently, there will will be two separate functional magnetic resonance imaging (fMRI) sessions in which lorazepam or placebo will be given prior to the MRI. During the fMRI the participants will also be asked to answer questions. Additionally, the participants will have their blood drawn, women of child bearing potential will have a urine pregnancy test, vital signs taken, and asked to complete more qols.

Description

  • Please note the collaborator (NIMH) is requesting that an NCT number be obtained prior to receiving the award number.
    • Initial assessment(s) may be done via videoconference due to Covid.

Details
Condition Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
Treatment Placebo and fMRI, Lorazepam and fMRI
Clinical Study IdentifierNCT04004416
SponsorUniversity of Michigan
Last Modified on12 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Meets DSM5 criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar disorder type 1, with history of psychosis, major depressive disorder, with history of psychosis, or other specified/unspecified psychotic disorder; or, meets SIPS criteria for Presence of Psychotic Symptoms or Brief Intermittent Psychotic Syndrome (BIPS)
Ability and willingness to give informed consent to participate
-35 years old
Positive symptom onset ≤ 2 years
No history of active substance use disorder in the past 2 months
Not currently on an involuntary treatment order
Not taking chronic narcotics, barbiturates, benzodiazepines
Absence of suicidal thoughts with plans or intentions, as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
No increases in psychotropic medication within the prior 4 weeks reflecting clinical instability and for half of EP sample, or not taking antipsychotic medication within the prior 4 weeks. Patients may take as needed doses of benzodiazepines as clinically prescribed, as long as those doses are not required within 5 half-lives of an MRI session
Ability to tolerate small, enclosed spaces without anxiety
No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition, e. g. aneurysm clips, retained particles (metal workers excluded), neurostimulators, foil-backed transdermal patches, carotid or cerebral stents, cerebral spinal fluid (CSF)shunts; magnetic dental implants, ferromagnetic ocular implants, pacemakers, automatic implantable defibrillators
Size compatible with scanner gantry, e. g. men over 6 feet tall that weigh more than 250 pounds (lbs), men under 6 feet tall that weigh over 220 lbs, women over 5'11" tall that weigh more than 220 lbs, or women under 5'10" tall that weigh more than 200 lbs. Subjects of these weights or greater typically have difficult fitting into the fMRI scanner properly
Exclusion
If a woman of child bearing age, not pregnant or trying to become pregnant
History of serious neurological illness or current medical condition that could compromise brain function, such as liver failure
History of closed head injury, for example (e.g.) loss of consciousness > ~5 min, hospitalization, neurological sequela
Schizophrenia/schizoaffective (SCZ) and bipolar affective disorder (BAD)
Inclusion Criteria
patients
Ability and willingness to give informed consent to participate
- 60 years old
Meets DSM- 5 criteria for schizophrenia, or schizoaffective disorder, or bipolar disorder type 1, with history of psychosis bipolar affective disorder
Duration of positive symptom onset > 2 years
No history of active substance use disorder in the past 2 months
Not currently on an involuntary treatment order
Not taking chronic narcotics, barbiturates, benzodiazepines
Absence of suicidal thoughts with plans or intentions, as assessed by C-SSRS
No increases in psychotropic medication within the prior 4 weeks reflecting clinical instability. Patients may take as needed doses of benzodiazepines as clinically prescribed, as long as those doses are not required within 5 half-lives of an MRI session
Ability to tolerate small, enclosed spaces without anxiety
No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition, e. g. aneurysm clips, retained particles (metal workers excluded), neurostimulators, foil-backed transdermal patches, carotid or cerebral stents, CSF shunts; magnetic dental implants, ferromagnetic ocular implants, pacemakers, automatic implantable defibrillators
Size compatible with scanner gantry, e. g. men over 6 feet tall that weigh more than 250 lbs, men under 6 feet tall that weigh over 220 lbs, women over 5'11" tall that weigh more than 220 lbs, or women under 5'10" tall that weigh more than 200 lbs. Subjects of these weights or greater typically have difficult fitting into the fMRI scanner properly
Exclusion
If a woman of child bearing age, not pregnant or trying to become pregnant
History of serious neurological illness or current medical condition that could compromise brain function, such as liver failure
History of closed head injury, for example (e.g.) loss of consciousness > ~5 min, hospitalization, neurological sequela
Healthy control subjects
Inclusion Criteria
Ability and willingness to give informed consent to participate
Age 16 - 60
No history of (h/o) past or current mental illness (except for simple phobias), but prior h/o substance abuse ok if in remission for greater than 5 years
Not taking any medication, prescription or non-prescription, with psychotropic effects (birth control medications allowed)
No first-degree family members with a history of a psychotic disorder (including bipolar disorder)
Ability to tolerate small, enclosed spaces without anxiety
No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition, e. g. aneurysm clips, retained particles (metal workers excluded), neurostimulators, foil-backed transdermal patches, carotid or cerebral stents, CSF shunts; magnetic dental implants, ferromagnetic ocular implants, pacemakers, automatic implantable defibrillators
Size compatible with scanner gantry, e. g. men over 6 feet tall that weigh more than 250 lbs, men under 6 feet tall that weigh over 220 lbs, women over 5'11" tall that weigh more than 220 lbs, or women under 5'10" tall that weigh more than 200 lbs. Subjects of these weights or greater typically have difficult fitting into the fMRI scanner properly
Exclusion
If a woman of child bearing age, not pregnant or trying to become pregnant
History of serious neurological illness or current medical condition that could compromise brain function, such as liver failure
History of closed head injury, for example (e.g.) loss of consciousness > ~5 min, hospitalization, neurological sequela
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note